LOS ANGELES, Feb. 14 (Xinhua) -- Women who receive an mRNA-based COVID-19 vaccination or booster during pregnancy can provide their infants with strong protection against symptomatic COVID-19 infection for at least six months after birth, according to a new study of the U.S. National Institutes of Health (NIH).
Earlier study revealed that when pregnant volunteers received both doses of an mRNA COVID-19 vaccine, antibodies induced by the vaccine could be found in their newborns' cord blood. This suggested that the infants likely had some protection against COVID-19 when they were still too young to receive a vaccine, NIH said in a release on Wednesday.
